- Rapid Release Technologies
- Issuing Office:
Los Angeles District
VIA UNITED PARCEL SERVICE
September 27, 2017
Dr. Stanley R. Stanbridge, Vice President of Research and Development/Owner
Rapid Release Technologies
3621 W. Macarthur Blvd, Ste. 111
Santa Ana, CA 92704-6843
Dear Dr. Stanbridge:
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter (WL #12-17), dated 01/17/2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Kelly D. Sheppard
Compliance Branch Director
Office of Medical Device and Radiological Health Operations